LISATHYONE 600 mg/3 ml Price

Overview

Welcome to Dwaey, specifically on LISATHYONE 600 mg/3 ml page.
This medicine contains an important and useful components, as it consists of
Glutathione is available in the market in concentration

Name

Miglitol

Precaution

Before taking **Miglitol**, it is essential to consult with a healthcare provider to ensure it is safe and appropriate for your individual needs. Key precautions include: - **Renal Impairment**: **Miglitol** should be used with caution in patients with **renal impairment**, as the drug is primarily excreted by the kidneys. A dose adjustment may be required for those with moderate to severe kidney dysfunction. - **Hepatic Disease**: Patients with **liver disease** should also be monitored closely, as **Miglitol** may affect liver function. Liver tests should be performed before initiating treatment. - **Gastrointestinal Disorders**: **Miglitol** can cause gastrointestinal (GI) discomfort, including bloating, flatulence, and diarrhea. It should be used cautiously in patients with existing GI conditions, such as **irritable bowel syndrome** or **inflammatory bowel disease**, as it may exacerbate these conditions. - **Hypoglycemia**: **Miglitol** alone does not typically cause hypoglycemia, but it can increase the risk of hypoglycemia when combined with **sulfonylureas** or **insulin**. Patients should be aware of the symptoms of low blood sugar and may need to adjust their diabetic medications accordingly. - **Pregnancy and Breastfeeding**: There is limited data on the use of **Miglitol** during pregnancy and breastfeeding. It is generally recommended to avoid **Miglitol** during pregnancy unless the benefits outweigh the risks, and it is unclear whether **Miglitol** passes into breast milk. Consultation with a healthcare provider is necessary for women who are pregnant or breastfeeding.

Indication

**Miglitol** is primarily prescribed for: - **Type 2 Diabetes Mellitus**: **Miglitol** is used as an oral **antidiabetic** medication to help control **blood sugar levels** in individuals with **type 2 diabetes**. It works by slowing the digestion and absorption of carbohydrates in the small intestine, thus preventing **postprandial hyperglycemia** (high blood sugar after meals). - **Postprandial Hyperglycemia**: In addition to helping control overall blood sugar levels, **Miglitol** specifically targets **postprandial** blood glucose levels, which are typically elevated in individuals with **type 2 diabetes**. By delaying carbohydrate absorption, it reduces the spike in glucose following meals.

Contra indication

**Miglitol** is contraindicated in certain conditions, including: - **Hypersensitivity**: **Miglitol** should not be used by individuals who have a known **allergy** or hypersensitivity to the drug or any of its components. - **Intestinal Obstructions**: **Miglitol** is contraindicated in patients with conditions that affect the **intestinal motility**, such as **bowel obstruction** or **inflammatory bowel disease**, as it can worsen these conditions. - **Severe Renal Impairment**: **Miglitol** is not recommended for patients with **severe renal dysfunction** (e.g., **creatinine clearance** < 25 mL/min), as it may accumulate in the body and lead to potential toxicity. - **Diabetic Ketoacidosis**: **Miglitol** is contraindicated in patients with **diabetic ketoacidosis**, a condition that occurs in people with diabetes, particularly type 1 diabetes, when insulin levels are too low, and blood glucose levels become dangerously high. - **Severe Liver Disease**: Patients with **severe liver disease** should avoid using **Miglitol** due to the lack of sufficient data on its safety and efficacy in this group.

Side Effect

Common and serious side effects of **Miglitol** may include: - **Gastrointestinal Disturbances**: The most frequent side effects are **flatulence**, **diarrhea**, **abdominal pain**, and **bloating**. These are due to the delayed digestion of carbohydrates in the small intestine, which can lead to fermentation and gas production. - **Hypoglycemia**: **Miglitol** alone is unlikely to cause significant hypoglycemia, but it can increase the risk when combined with other antidiabetic medications such as **insulin** or **sulfonylureas**. Symptoms of low blood sugar may include dizziness, sweating, and confusion. - **Liver Function Changes**: Although rare, some patients may experience elevated liver enzymes, which could indicate liver damage. Regular liver function tests are recommended when starting treatment. - **Headache and Fatigue**: Some patients may experience **headaches** or **fatigue** as part of the body adjusting to the medication. These effects are usually mild and tend to subside over time. - **Severe Abdominal Discomfort**: In rare cases, patients may experience **severe abdominal discomfort**, which should be reported to a healthcare provider if it persists or becomes problematic. - **Severe Hypoglycemia**: **Miglitol** can increase the risk of severe hypoglycemia when combined with other hypoglycemic agents, especially **insulin**. This may require prompt treatment with glucose.

Pregnancy Category ID

2

Mode of Action

**Miglitol** is an **alpha-glucosidase inhibitor** that works by slowing the digestion and absorption of carbohydrates in the small intestine. The primary mechanism of action includes: - **Inhibition of Alpha-Glucosidase**: **Miglitol** inhibits the enzyme **alpha-glucosidase**, which is responsible for breaking down carbohydrates into smaller sugars (like glucose). By inhibiting this enzyme, **Miglitol** delays the conversion of carbohydrates into simple sugars, resulting in a **slower and lower increase in blood sugar** after meals. - **Reduction of Postprandial Hyperglycemia**: This action helps to prevent the sharp **blood sugar spikes** that typically occur after eating, which is particularly beneficial for people with **type 2 diabetes** who have difficulty managing post-meal glucose levels.

Interaction

Several drug interactions may affect the safety or effectiveness of **Miglitol**, including: - **Antidiabetic Agents**: When used in combination with other **antidiabetic** medications, such as **sulfonylureas** or **insulin**, **Miglitol** can increase the risk of **hypoglycemia** (low blood sugar), especially if meals are skipped or if doses are not adjusted appropriately. - **Digestive Enzyme Substitutes**: **Miglitol** can interfere with the absorption of **carbohydrates** and may reduce the effectiveness of digestive enzyme substitutes like **amylase** and **lipase**. These interactions may diminish the therapeutic effect of some gastrointestinal therapies. - **Metformin**: When used with **metformin**, a commonly prescribed **biguanide**, the combined effect on blood glucose can be additive, leading to a more significant decrease in blood sugar. Monitoring of blood glucose levels is essential when these two medications are used together. - **Probenecid**: The use of **probenecid**, a medication used for gout, may reduce the renal excretion of **Miglitol**, increasing the drug's concentration in the blood. Close monitoring and dose adjustments are recommended. - **Ciprofloxacin**: This antibiotic may alter blood sugar levels, leading to either an increase or decrease in blood sugar. **Miglitol** may exacerbate this effect, requiring careful blood sugar monitoring when the two drugs are used together.

Pregnancy Category Note

Information not available

Adult Dose

The recommended dose of **Miglitol** for adults with type 2 diabetes is: - **Starting Dose**: **25 mg** taken orally **three times a day** with the first bite of each main meal. - **Maintenance Dose**: The dose may be increased gradually, based on the patient’s tolerance and therapeutic response, up to a maximum dose of **100 mg** three times a day. - **Adjustment for Renal Impairment**: Patients with renal impairment may require a lower dose, with careful monitoring of kidney function during treatment.

Child Dose

**Miglitol** is not generally approved for use in children. There is insufficient data on the safety and efficacy of **Miglitol** in pediatric populations. If used in children, it should only be under strict medical supervision with careful dosing adjustments and monitoring. As always, it is critical for patients to consult their healthcare provider before initiating **Miglitol** to ensure it is the right choice for their condition and that proper monitoring is in place.

Renal Dose

**Miglitol** should be used with caution in patients with renal impairment: - For patients with mild to moderate renal impairment (**creatinine clearance ≥ 25 mL/min**), the usual dose may be used with close monitoring. - In patients with **severe renal impairment** (creatinine clearance < 25 mL/min), the use of **Miglitol** is not recommended unless the potential benefits outweigh the risks. A lower dose may be considered, but renal function should be closely monitored.

Administration

Information not available